On 11 January 2016, orphan designation (EU/3/15/1600) was granted by the European Commission to Syri Limited, United Kingdom, for sodium benzoate for the treatment of hyperargininaemia.

The sponsorship was transferred to Syri Pharma Limited, Ireland, in August 2019.

Key facts

Active substance
Sodium benzoate
Disease / condition
Treatment of hyperargininaemia
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Syri Pharma Limited
Floor 0
1 Windmill Lane
Dublin 2 
D02 F206

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating